Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for aspirin
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.
Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.
Research evidence, clinical trials and guidelines on Aspirin
Systematic review: interactions between aspirin, and other nonsteroidal anti-inflammatory drugs, and polymorphisms in relation to colorectal cancer. Nonsteroidal anti-inflammatory drugs (NSAIDs) include aspirin (acetylsalicylicacid, ASA). Long-term use of NSAIDs has been associated with lowered risk of colorectal cancer (CRC), but the use is hampered by adverse effects. Also, the anti-carcinogenic effects of NSAIDs are incompletely understood. Understanding biological effects of NSAIDs may (...) help developing new preventive medical strategies.To identify gene-environment interactions between genetic variation and NSAID use in relation to risk of CRC.We performed a PubMed literature search and all studies reporting original data on interactions between NSAIDs and polymorphisms in relation to CRC were evaluated.We found indications that aspirin interacted with rs6983267 close to MYC (encoding a transcription factor involved in cell cycle progression, apoptosis and cellular transformation
Aspirin and non-aspirin NSAIDs increase risk of colonic diverticular bleeding: a systematic review and meta-analysis. Lower gastrointestinal bleeding is a frequent cause of hospitalization, particularly in the elderly, and its incidence appears to be on the rise. Colonic diverticular bleeding is the most common form of lower gastrointestinal bleeding and is responsible for 30-40 % of bleeding episodes. Risk factors associated with diverticular bleeding include obesity, hypertension (...) calculated with fixed-effects and random-effects models. A total of six studies (five case-control studies and one cohort study) met inclusion criteria for analysis. Non-aspirin NSAIDs (NANSAIDs) and aspirin were associated with an increased risk of colonic diverticular bleeding (summary RR = 2.48, 95 % CI 1.86-3.31), with moderate heterogeneity among these studies (P heterogeneity = 0.11, I (2) = 44.4 %). Stratification to evaluate the heterogeneity found that both NANSAIDs (summary RR = 2.24, 95 % CI
Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force Henderson JT, Whitlock EP (...) , O'Connor E, Senger CA, Thompson JH, Rowland MG Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Henderson JT, Whitlock EP, O'Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for the prevention of morbidity and mortality from pre-eclampsia: a systematic evidence review for the U.S. preventive services task force. Rockville: Agency
Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality.To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia.MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled Trials (January 2006 to June 2013 (...) , in addition to 6 RCTs and 2 observational studies of average-risk women to assess harms (7 good-quality). Depending on baseline risk, aspirin use was associated with absolute risk reductions of 2% to 5% for preeclampsia (relative risk [RR], 0.76 [95% CI, 0.62 to 0.95]), 1% to 5% for intrauterine growth restriction (RR, 0.80 [CI, 0.65 to 0.99]), and 2% to 4% for preterm birth (RR, 0.86 [CI, 0.76 to 0.98]). No significant perinatal or maternal harms were identified, but rare harms could not be ruled out
Effect of aspirin and other non-steroidal anti-inflammatory drugs on prostate cancer incidence and mortality: a systematic review and meta-analysis. It has been postulated that non-steroidal anti-inflammatory drugs (NSAIDs) use leads to decreased prostate cancer (PCa) risk. In recent years, NSAIDs' role in PCa development has been extensively studied; however, there is not yet a definitive answer. Moreover, the epidemiological results for NSAIDs' effect on PCa-specific mortality have been (...) performed.Thirty-nine studies (20 case-control and 19 cohort studies) were included in this analysis. Thirty-one studies were available concerning NSAID use and PCa incidence and eight studies on PCa-specific mortality. Compared to non-use, aspirin use was statistically significantly associated with PCa incidence risk, and the association was slightly stronger for advanced PCa than for total PCa (OR = 0.92, 95% CI = 0.87 to 0.97 for total PCa; OR = 0.81, 95% CI = 0.73 to 0.89 for advanced PCa). Aspirin use
Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in patients with atrial fibrillation: a pilot study Current stroke risk schemes need improvement of predictive value in patients with atrial fibrillation. Transoesophageal echocardiography (TEE) may facilitate stroke risk assessment in such patients and guide antithrombotic treatment.We randomised 238 patients with non-valvular atrial fibrillation and a moderate stroke risk to aspirin or adjusted vitamin K (...) antagonist therapy after TEE had ruled out thrombogenic features in the atria and aorta. The primary outcome was a composite of stroke, major bleeding, peripheral embolism and all-cause mortality.Mean CHA2DS2-VASc score was 2.1±1.1. The incidences of the composite primary outcome at a mean follow-up of 1.6 years were 3.2% (2.02% per year) in the aspirin group compared to 6.1% (3.84% per year) in the vitamin K antagonists group with an absolute advantage of 2.9 percentage points. Aspirin was non-inferior
Association Between Aspirin Use and Age-Related Macular Degeneration：A Meta-Analysis. We conducted a meta-analysis of randomized controlled trials (RCTs) and observational studies to evaluate the association between aspirin use and age-related macular degeneration (AMD).The pertinent studies were identified via literature search through four databases (MEDLINE, Web of Science, Cochrane Library, Embase) and reference lists of retrieved studies. Randomized controlled trials and cohort (...) effect of all nine studies showed no significant association between aspirin use and occurrence of AMD (RR, 1.00; 95% CI 0.96-1.04), and no significant association was observed in any specific study design (RR, 0.93; 95% CI 0.71-1.22 for RCT; RR, 1.02; 95% CI 0.87-1.20 for cohort study; RR, 1.00; 95% CI 0.96-1.04 for case-control study). However, subgroup analysis showed aspirin use to be significantly associated with an increased risk of neovascular AMD (RR, 1.59; 95% CI 1.09-2.31).The pooled
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. Regular aspirin use is associated with reduced risk of several malignancies. Epidemiologic studies analyzing aspirin, nonaspirin nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen use and ovarian cancer risk have been inconclusive.We analyzed pooled data from 12 population-based case-control (...) with a reduced risk of ovarian cancer (OR = 0.91; 95% confidence interval [CI] = 0.84 to 0.99). Results were similar but not statistically significant for nonaspirin NSAIDs, and there was no association with acetaminophen. In seven studies with frequency data, the reduced risk was strongest among daily aspirin users (OR = 0.80; 95% CI = 0.67 to 0.96). In three studies with dose information, the reduced risk was strongest among users of low dose (<100 mg) aspirin (OR = 0.66; 95% CI = 0.53 to 0.83), whereas
Codeine and acetylsalicylicacid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence Codeine and acetylsalicylicacid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence Codeine and acetylsalicylicacid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Codeine and acetylsalicylicacid for the management of post-tonsillectomy or adenoidectomy pain: a review of the clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013 Authors' conclusions No relevant literature was identified regarding the risk of bleeding associated with the use of codeine
Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and interventional studies identified from the Medline, Embase and Cochrane databases were selected if they assessed the incidence of first thrombosis (...) in aPL+ patients treated with aspirin versus those without. Pooled effect estimates were obtained using a random-effects model. Of 1211 citation retrieved, 11 primary studies (10 observational and 1 interventional) met inclusion criteria, including a total of 1208 patients and 139 thrombotic events. The pooled odds ratio (OR) for the risk of first thrombosis in patients treated with aspirin (n=601) was 0.50 (95%CI: 0.27 to 0.93) compared to those without aspirin (n=607), with significant
concentrations. Elimination of ASA is almost exclusively by hydrolysis to salicylicacid (around 1% of ASA dose is excreted unhydrolyzed by the kidney) and starts already in the gut wall. Elimination of acetylsalicylicacid is a first-order process at concentrations in the range between 100-300 µg/mL with a half-life of around 2- 3 hours. 18.104.22.168. Bioequivalence study 22.214.171.124.1. Methodology – Study design Medicinal product no longer authorised Assessment report EMA/CHMP/333195/2014 Page 22/43 This is an open (...) 2.5. Clinical safety 30 2.6. Pharmacovigilance 33 2.7. Risk Management Plan 34 2.8. Product information 39 3. Benefit-Risk Balance 39 Benefit-risk balance 41 4. Recommendations 42 Medicinal product no longer authorised Assessment report EMA/502333/2014 Page 3/43 List of abbreviations AA Arachidonic acid ACE Angiotensin converting enzyme ACS Acute coronary syndrome ADP Adenosine diphosphate AE Adverse event Al(u) Aluminium ANOVA Analysis of variance ASAAcetylsalicylicacid AUC Area under the curve
. The incidence and severity of premature closure of the ductus arteriosus appears to be dose-related and increases with advancing gestational age beyond 30 weeks. Early obstetric or fetal medicine input is recommended for cases of aspirin overdose in the third trimester as early delivery or additional monitoring may be indicated. Appropriate maternal treatment of aspirin overdose is important to reduce the risk of salicylate toxicity in both the mother and the fetus. There are no published guidelines (...) Aspirin overdose ASPIRIN OVERDOSE IN PREGNANCY 0344 892 0909 ASPIRIN OVERDOSE IN PREGNANCY (Date of issue: December 2012 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Low-dose aspirin (75-300mg/day) is used as an antiplatelet medication to reduce the risk of thrombosis in cerebrovascular
Aspirin USE OF ASPIRIN IN PREGNANCY 0344 892 0909 USE OF ASPIRIN IN PREGNANCY (Date of issue: July 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Low-dose aspirin (75-300mg/day) is used as an antiplatelet medication (...) in the prophylaxis of thromboembolic cerebrovascular disease, myocardial infarction and pre-eclampsia. Higher doses of aspirin (up to 4g/day) are used in the control of mild to moderate pain and pyrexia. There is a large body of evidence that shows no association between the use of low-dose aspirin (LDA) during pregnancy and increased risk of spontaneous abortion or stillbirth. Fewer data are available regarding aspirin use at analgesic doses, but again no association with these two outcomes has been reported
profile and consult your decision boxes. Email Password Stay logged in: Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. Create an account Title Full Name Email * Choose a username Password * Please enter a password Repeat Password * Both passwords do not fit Aspirin for cardiovascular disease Acetylsalicylicacid (ASA) for primary prevention of cardiovascular disease Presenting ASA to patients To know more (...) Acetylsalicylicacid (ASA) for primary prevention of cardiovascular disease Boîte à décision | Pdf boxe Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your
ASA Physical Status Classification System ASA Physical Status Classification System | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Quality and Practice Management Back Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member (...) Center About ASA Back About ASA ASA Physical Status Classification System Developed By: ASA House of Delegates/Executive Committee Last Amended: October 15, 2014 (original approval: October 15, 2014) Current definitions (NO CHANGE) and Examples (NEW) ASA PS Classification Definition Examples, including, but not limited to: ASA I A normal healthy patient Healthy, non-smoking, no or minimal alcohol use ASA II A patient with mild systemic disease Mild diseases only without substantive functional
Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Preconception-initiated low-dose aspirin might positively affect pregnancy outcomes, but this possibility has not been adequately assessed. Our aim was to investigate whether low-dose aspirin improved livebirth rates in women with one to two previous pregnancy losses.In this multicentre, block-randomised, double-blind, placebo-controlled trial, women aged 18-40 years who were attempting to become (...) pregnant were recruited from four medical centres in the USA. Participants were stratified by eligibility criteria--the original stratum was restricted to women with one loss at less than 20 weeks' gestation during the previous year, whereas the expanded stratum included women with one to two previous losses, with no restrictions on gestational age or time of loss. Women were block-randomised by centre and eligibility stratum in a 1:1 ratio. Preconception-initiated daily low-dose aspirin (81 mg per day
Aspirin in Patients Undergoing Noncardiac Surgery. There is substantial variability in the perioperative administration of aspirin in patients undergoing noncardiac surgery, both among patients who are already on an aspirin regimen and among those who are not.Using a 2-by-2 factorial trial design, we randomly assigned 10,010 patients who were preparing to undergo noncardiac surgery and were at risk for vascular complications to receive aspirin or placebo and clonidine or placebo. The results (...) of the aspirin trial are reported here. The patients were stratified according to whether they had not been taking aspirin before the study (initiation stratum, with 5628 patients) or they were already on an aspirin regimen (continuation stratum, with 4382 patients). Patients started taking aspirin (at a dose of 200 mg) or placebo just before surgery and continued it daily (at a dose of 100 mg) for 30 days in the initiation stratum and for 7 days in the continuation stratum, after which patients resumed